Edgar Filing: Jazz Pharmaceuticals plc - Form 4

	aceuticals plc									
Form 4										
March 05, 2	2014									
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION							OMB APPROVAL			
Washington, D.C. 20549						OMMISSION	OMB Number:	3235-0287		
Check t if no lor	agor						Expires:	January 31, 2005 average		
subject			GES IN BENEFICIAL OWNE			Estimated a				
Section		SECURITIES				ES				
Form 4 Form 5			1((-)) = f(+) = 0	·····	1	A - 4 - 6 1024	response 0.5			
obligati	000	rsuant to Section			-					
may con	ntinue.	(a) of the Public $20(h)$ of the	Investment Cor	· ·						
See Inst	ruction	50(II) of the		npany Act	01 1940					
1(b).										
(Print or Type	Responses)									
	•									
					-0	5. Relationship of Reporting Person(s) to Issuer				
wiumgan o	cantus									
Jazz Pi			Pharmaceuticals plc [JAZZ]			(Check all applicable)				
			of Earliest Transaction							
			/Day/Year)		-	X_ Director 10% Owner Officer (give title Other (specify				
			/2014	b	below) below)					
			nendment, Date Original			6. Individual or Joint/Group Filing(Check				
			Ionth/Day/Year)	0		Applicable Line)				
				-	_X_Form filed by One Reporting Person Form filed by More than One Reporting					
DUBLIN 2	2, L2				– F	Form filed by Mc Person	ore than One Rej	porting		
(City)	(State)	(Zip) Te				1		0		
(;))		12			_	red, Disposed of,	or Beneficial	-		
1.Title of	2. Transaction Date		n Date, if Transactionor Disposed of (D) Code (Instr. 3, 4 and 5)			5. Amount of	6. Oran analain	7. Nature of		
Security (Instr. 3)	(Month/Day/Year)	Execution Date, if any				Securities Beneficially Owned	Ownership Form:	Indirect Beneficial		
(111541-0)		(Month/Day/Year)					Direct (D)	Ownership		
						Following	or Indirect	(Instr. 4)		
				(A)		Reported Transaction(s)	(I) (Instr. 4)			
				or		(Instr. 3 and 4)	(Insu. 4)			
0.1			Code V Am	ount (D)	Price	(
Ordinary Shares	03/04/2014(1)		S <u>(1)</u> 550	,000 D	\$ 156.25	1,455,555 <u>(1)</u>	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	5		7. Titl Amou Under Securi (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
		Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: Jazz Pharmaceuticals plc - Form 4

Reporting Owners

Reporting Owner Name / Addre	SS	Relationships						
	Director	10% Owner	Officer	Other				
Mulligan Seamus 45 FITZWILLIAM SQUAR DUBLIN 2, L2	E X							
Signatures								
/s/ Seamus Mulligan	03/05/2014							
<u>**</u> Signature of Reporting Person	Date							

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) On March 4, 2014, the Reporting Person completed the sale of 550,000 ordinary shares pursuant to Rule 144.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.